东宝生物
(300239)
| 流通市值：31.26亿 | | | 总市值：31.46亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 188,034,307.73 | 884,932,215.88 | 633,112,065.92 | 444,275,439.67 |
| 营业收入 | 188,034,307.73 | 884,932,215.88 | 633,112,065.92 | 444,275,439.67 |
| 二、营业总成本 | 165,982,769.88 | 784,300,105.92 | 555,269,833.32 | 383,990,220.35 |
| 营业成本 | 140,917,714.68 | 683,859,412.69 | 489,880,095.68 | 343,596,466.41 |
| 税金及附加 | 2,601,869.28 | 9,809,271.24 | 6,864,108.18 | 4,788,685.67 |
| 销售费用 | 3,973,926.36 | 18,695,645.02 | 12,635,523.41 | 7,985,769.47 |
| 管理费用 | 12,990,219.57 | 49,965,485.13 | 33,584,181.69 | 21,357,197.04 |
| 研发费用 | 5,722,250.85 | 27,361,788.76 | 16,012,452.92 | 8,976,532.89 |
| 财务费用 | -223,210.86 | -5,391,496.92 | -3,706,528.56 | -2,714,431.13 |
| 其中:利息费用 | 726,987.63 | 2,564,535.38 | 1,959,679.91 | 1,284,510.01 |
| 其中:利息收入 | 831,304.14 | 7,114,485.65 | 5,517,789.65 | 3,557,296.32 |
| 加:投资收益 | -576,059.12 | -3,743,341.08 | -3,007,719.11 | -2,215,682.57 |
| 资产处置收益 | 10,571.31 | -284,115.61 | -277,943.39 | -278,808.13 |
| 资产减值损失(新) | -1,519,552.08 | -3,316,535.41 | -1,548,347.56 | -394,495.25 |
| 信用减值损失(新) | 137,864.54 | 525,527.93 | 552,636.23 | 385,153.47 |
| 其他收益 | 2,188,036.21 | 12,367,917.13 | 9,035,682.43 | 6,657,354.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,292,398.71 | 106,181,562.92 | 82,596,541.2 | 64,438,741.48 |
| 加:营业外收入 | 142,580.56 | 341,822.39 | 116,706.7 | 109,906.65 |
| 减:营业外支出 | 1,907.09 | 890,408.01 | 890,452.41 | 883,312.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 22,433,072.18 | 105,632,977.3 | 81,822,795.49 | 63,665,335.47 |
| 减:所得税费用 | 3,388,371.44 | 14,368,848.66 | 10,287,606.93 | 8,224,065.18 |
| 六、净利润 | 19,044,700.74 | 91,264,128.64 | 71,535,188.56 | 55,441,270.29 |
| 持续经营净利润 | 19,044,700.74 | 91,264,128.64 | 71,535,188.56 | 55,441,270.29 |
| 归属于母公司股东的净利润 | 19,044,819.05 | 85,982,726.28 | 66,273,700.7 | 51,341,802.92 |
| 少数股东损益 | -118.31 | 5,281,402.36 | 5,261,487.86 | 4,099,467.37 |
| (一)基本每股收益 | 0.03 | 0.14 | 0.11 | 0.09 |
| (二)稀释每股收益 | 0.03 | 0.13 | 0.1 | 0.08 |
| 九、综合收益总额 | 19,044,700.74 | 91,264,128.64 | 71,535,188.56 | 55,441,270.29 |
| 归属于母公司股东的综合收益总额 | 19,044,819.05 | 85,982,726.28 | 66,273,700.7 | 51,341,802.92 |
| 归属于少数股东的综合收益总额 | -118.31 | 5,281,402.36 | 5,261,487.86 | 4,099,467.37 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-28 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |